Kissei Pharmaceutical Co., Ltd

(PINK:KSPHF)

Latest On Kissei Pharmaceutical Co., Ltd (KSPHF):

Date/Time Type Description Signal Details
2021-03-30 06:18 ESTDividendA dividend of $27 has been announced on May 12, 2020. It will be paid Nov 30, -0001 with an ex-dividend date of Mar 30, 2021.Neutral
2021-02-03 14:11 ESTFinancialsCompany financials have been released.Neutral
2020-12-04 18:36 ESTFinancialsCompany financials have been released.Neutral
2020-11-27 00:04 ESTFinancialsCompany financials have been released.Neutral
2020-11-17 14:26 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 19:14 ESTFinancialsCompany financials have been released.Neutral
2020-11-06 10:16 ESTFinancialsCompany financials have been released.Neutral
2020-10-08 20:10 ESTFinancialsCompany financials have been released.Neutral
2020-09-26 16:05 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 08:43 ESTFinancialsCompany financials have been released.Neutral
2020-08-14 12:09 ESTFinancialsCompany financials have been released.Neutral
2020-08-07 11:14 ESTFinancialsCompany financials have been released.Neutral
2020-08-06 15:48 ESTFinancialsCompany financials have been released.Neutral
2020-08-04 19:04 ESTFinancialsCompany financials have been released.Neutral
2020-07-31 11:29 ESTFinancialsCompany financials have been released.Neutral
2020-07-31 03:48 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 19:58 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 07:57 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 00:11 ESTFinancialsCompany financials have been released.Neutral
2020-07-28 16:48 ESTFinancialsCompany financials have been released.Neutral
2020-07-27 23:09 ESTFinancialsCompany financials have been released.Neutral
2020-07-27 15:46 ESTFinancialsCompany financials have been released.Neutral
2020-07-09 11:58 ESTFinancialsCompany financials have been released.Neutral
2020-07-09 06:55 ESTFinancialsCompany financials have been released.Neutral
2020-07-01 19:37 ESTFinancialsCompany financials have been released.Neutral
2020-07-01 03:29 ESTFinancialsCompany financials have been released.Neutral
2020-06-25 06:50 ESTFinancialsCompany financials have been released.Neutral
2020-06-19 15:31 ESTFinancialsCompany financials have been released.Neutral
2020-06-14 07:41 ESTFinancialsCompany financials have been released.Neutral
2020-06-12 09:14 ESTFinancialsCompany financials have been released.Neutral
2020-06-05 14:58 ESTFinancialsCompany financials have been released.Neutral
2020-06-03 18:52 ESTFinancialsCompany financials have been released.Neutral
2020-05-27 08:18 ESTFinancialsCompany financials have been released.Neutral
2020-05-21 04:01 ESTFinancialsCompany financials have been released.Neutral
2020-05-07 03:16 ESTFinancialsCompany financials have been released.Neutral
2020-05-06 08:38 ESTFinancialsCompany financials have been released.Neutral
2020-05-02 23:09 ESTFinancialsCompany financials have been released.Neutral
2020-05-01 19:28 ESTFinancialsCompany financials have been released.Neutral
2020-04-30 06:57 ESTFinancialsCompany financials have been released.Neutral
2020-04-23 06:52 ESTFinancialsCompany financials have been released.Neutral
2020-04-23 03:06 ESTFinancialsCompany financials have been released.Neutral
2020-04-20 07:15 ESTFinancialsCompany financials have been released.Neutral
2020-04-16 19:02 ESTFinancialsCompany financials have been released.Neutral
2020-04-16 15:01 ESTFinancialsCompany financials have been released.Neutral
2020-04-16 10:43 ESTFinancialsCompany financials have been released.Neutral
2020-04-16 02:51 ESTFinancialsCompany financials have been released.Neutral

About Kissei Pharmaceutical Co., Ltd (KSPHF):

Kissei Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products primarily in Japan. It offers Urief and Urief OD tablets for the treatment of dysuria; Glufast, Glubes, and Marizev tablets for type 2 diabetes; Darbepoetin Alfa BS and Epoetin Alfa BS injections for the treatment of renal anemia; Beova tablets for overactive bladder treatment; P-TOL chewable tablets for treating hyperphosphatemia; and Minirin Melt OD tablets for nocturia due to nocturnal polyuria in males, central diabetes insipidus, and nocturnal enuresis resulted from decrease of urine osmolality. The company's products in pipeline include KPS-0373 that has completed Phase III clinical trial to treat spinocerebellar ataxia; CCX168, which has completed Phase III clinical trial for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis; AJM300, which is in Phase III clinical trial to treat ulcerative colitis; R788 that is in Phase III clinical trial to treat chronic idiopathic thrombocytopenic purpura; and MR13A9, which is in Phase III clinical trial to treat uremic pruritus in dialysis patients. It is also developing KLH-2109 for treating endometriosis and uterine fibroids; KDT-3594 for the treatment of Parkinson's disease; Silodosin for dysuria associated with benign prostatic hyperplasia; Mitiglinide for type 2 diabetes mellitus; and Bedoradrine for the treatment of acute exacerbation of asthma. In addition, it develops and sells protein controlled and energy supply foods; and purchases and sells related materials, as well as offers system development and information processing, construction contracting, equipment and facility management, and information gathering and development support services. The company was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. The company was founded in 1946 and is headquartered in Matsumoto, Japan.

See Advanced Chart

General

  • Name Kissei Pharmaceutical Co., Ltd
  • Symbol KSPHF
  • Type Common Stock
  • Exchange PINK
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryDrug Manufacturers-Specialty & Generic
  • Full Time Employees 1,892
  • Fiscal Year EndMarch
  • Web URLhttp://www.kissei.co.jp
View More

Valuation

  • Trailing PE 19.84
  • Price/Sales (Trailing 12 Mt.) 1.69
  • Price/Book (Most Recent Quarter) 0.53
  • Enterprise Value Revenue 0.01
  • Enterprise Value EBITDA 0.07
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Profit Margin 9%
  • Return on Assets 1%
  • Return on Equity 3%
  • Revenue Per Share $0
  • Gross Profit 34.91 billion
  • Quarterly Earnings Growth 17.1%
View More

Highlights

  • Market Capitalization 1.03 billion
View More

Share Statistics

  • Shares Outstanding 46.72 million
  • Shares Float 40.85 million
  • % Held by Insiders 2386%
  • % Held by Institutions 27.61%
View More

Technicals

  • Beta 0.61
  • 52 Week High $25.5
  • 52 Week Low $19.7
  • 50 Day Moving Average 22.2
  • 200 Day Moving Average 21.65
View More

Dividends

  • Forward Annual Dividend Rate $0.52
  • Forward Annual Dividend Yield 2.33%
  • Payout Ratio 3084%
  • Dividend Date N/A
  • ExDividend Date 2020-09-29
  • Dividend Per Share $0.52
  • Dividend Yield 0%
View More

Kissei Pharmaceutical Co., Ltd (KSPHF) Dividend Calendar:

Kissei Pharmaceutical Co., Ltd pays out 3084% of its earnings out as a dividend.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Kissei Pharmaceutical Co., Ltd (KSPHF) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.

KSPHF's next estimated earnings release date is June 30, 2021.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312020-12-31$N/A$0.42
2020-09-302020-12-31$N/A$0.42$15.00-97.18%
2020-06-302020-09-30$N/A$0.54$17.05-96.82%
2020-03-312020-06-30$N/A$0.34
2019-12-312020-03-31$17 billion-$0.14
2019-09-302019-12-31$15.45 billion$0.27
2019-06-302019-09-30$16.11 billion$0.03$25.70-99.89%
2019-03-312019-06-30$17.04 billion$0.40
2018-12-312019-03-31$19.59 billion$0.23
2018-09-302018-12-31$17.81 billion$0.18
2018-06-302018-09-30$17.85 billion$0.11$41.60-99.73%
2018-03-312018-06-30$17.22 billion$0.53
2017-12-312018-03-31$20.2 billion$0.20
2017-09-302017-12-31$17.74 billion$0.69
2017-06-302017-09-30$18.85 billion$0.40
2017-03-312017-06-30$17.1 billion$0.39
2016-12-312017-03-31$0.13
2016-09-302016-12-31$0.56
2016-06-302016-09-30$0.21$33.70-99.37%
2016-03-312016-06-30$0.56
2015-12-312016-03-31-$0.12$0.00
2015-09-302015-12-31$0.83$0.00
2015-06-302015-09-30$0.29$49.41-99.42%
2015-03-312015-06-30$0.38$0.00
2014-12-312015-03-31-$0.05$34.20-100.14%
2014-09-302014-12-31$0.49$0.00
2014-06-302014-09-30$0.40$0.00
2014-03-312014-06-30$0.44$0.00
2013-12-312014-03-31$0.07$0.00
2013-09-302013-12-31$0.91$0.00
2013-06-302013-09-30$0.27$0.00
2013-03-312013-06-30$0.48$0.00
2012-12-312013-03-31$0.13$0.00
2012-09-302012-12-31$0.57$0.00
2012-06-302012-09-30$0.09$0.00
2012-03-312012-06-30$0.35$0.00
2011-12-312012-03-31$0.19$0.00
2011-09-302011-12-31$0.38$0.00
2011-06-302011-09-30$0.28$0.00
2011-03-312011-06-30$0.31$0.00
2010-12-312011-03-31$0.17$0.00
2010-09-302010-12-31$0.41$0.00

Kissei Pharmaceutical Co., Ltd (KSPHF) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Kissei Pharmaceutical Co., Ltd (KSPHF) Chart:

Kissei Pharmaceutical Co., Ltd (KSPHF) News:

Below you will find a list of latest news for Kissei Pharmaceutical Co., Ltd (KSPHF) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Kissei Pharmaceutical Co., Ltd (KSPHF) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Kissei Pharmaceutical Co., Ltd (KSPHF) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link